Biopharmaceutical company AMO Pharma Limited reported on Thursday the addition of Julia Jones as chief financial officer (CFO) as well as a member of its board of directors.
As part of the pharma team, Jones said she will apply her experience to help the company maximize the full range of opportunities associated with their leadership in research and product development based on continuing progress in their late-stage clinical programmes.
Previously, Jones was a chartered accountant at PricewaterhouseCoopers as well as founder of Archangel Accounting Ltd, a UK-based finance and accounting firm, where she provided senior counsel and services to many public and private life sciences companies.
According to the company, Jones has an established record of supporting life sciences companies at every stage of development from start up through to exit and has helped companies secure and manage significant investments in venture capital funding.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study